News

Pharmabiz13h
Synendos Therapeutics appoints Dr. George Garibaldi to move phase 2 clinical development of its lead drug asset SYT-510
Synendos Therapeutics appoints Dr. George Garibaldi to move phase 2 clinical development of its lead drug asset SYT-510: Basel, Switzerland Wednesday, July 16, 2025, 15:45 Hrs [IS ...
Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly- ...
Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules
Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK, July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy ...